CBX

 CSPC Pharmaceutical is conducting a phase 2 study (CTR20241075) for nonsegmental vitiligo of SYHX1901, an oral JAK/SYK inhibitor. The first phase 2 study for psoriasis began in March 2023.  The first-in-human study, initiated in healthy participants in 2021, has been completed in 2022. The study was aimed at patients with SLE and RA. SYHX1901 SYHX1901 is a dual inhibitor of JAK and SYK, expected to be effective in treating autoimmune diseases such as psoriasis, lupus, and vitiligo. In 2023, CSPC filed a patent (WO2022188796) covering the use of a compound containing a tricyclic heteroaryl group for the treatment of autoimmune disease.  2021 Patent The IC 50 values for the compound I were measured against JAK1, JAK2, JAK3, TYK2, and SYK, yielding values of 20.04 nM, 3.92 nM, 1.43 nM, 0.82 nM, and 7.25 nM, respectively. Efficacies for psoriasis, atopic dermatitis, and SLE were tested in the IMQ-induced model, OXA-induced model, and SLE model mice.  Efficacy results in SLE model Accordi

  CSPC and its subsidiary, Megalith Biopharma, have submitted the Investigational New Drug (IND) application for SYS6023, an anti-HER3 ADC, in China. SYS6023 In 2021, Megalith Biopharma filed a patent (WO2023088382) covering anti-HER2, anti-HER3, and anti-EGFR ADC, as well as the use thereof. Megalith made a notable change to the payload, opting for JSSW-001, which differs from Daiichi Sankyo's Patritumab deruxtecan (HER3-DXd). In experiments involving the Difi and SW620 colorectal cancer models, the Tumor Growth Inhibition (TGI) of Patritumab-JSSW-001 (DAR=7.36) exceeded that of the HER3 DXd. Anti-HER3 ADC in China SHR-A2009 Hengrui's anti-HER3 ADC, SHR-A2009, is currently in phase 1/2 trials, both as a monotherapy and in combination with Adebrelimab (anti-PD-L1 mAb) or Almonertinib (EGFRi) for non-small cell lung cancer (NSCLC). The first IND application for SHR-A2009 was submitted in August 2021. In October 2023, Hengrui reported the results of phase 1 trial: In evaluable NS